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Abstract
Although several prognostic signatures have been developed in lung cancer, their application in clinical practice has been
limited because they have not been validated in multiple independent data sets. Moreover, the lack of common genes
between the signatures makes it difficult to know what biological process may be reflected or measured by the signature.
By using classical data exploration approach with gene expression data from patients with lung adenocarcinoma (n = 186),
we uncovered two distinct subgroups of lung adenocarcinoma and identified prognostic 193-gene gene expression
signature associated with two subgroups. The signature was validated in 4 independent lung adenocarcinoma cohorts,
including 556 patients. In multivariate analysis, the signature was an independent predictor of overall survival (hazard ratio,
2.4; 95% confidence interval, 1.2 to 4.8; p= 0.01). An integrated analysis of the signature revealed that E2F1 plays key roles in
regulating genes in the signature. Subset analysis demonstrated that the gene signature could identify high-risk patients in
early stage (stage I disease), and patients who would have benefit of adjuvant chemotherapy. Thus, our study provided
evidence for molecular basis of clinically relevant two distinct two subtypes of lung adenocarcinoma.
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Introduction
Lung cancer is one of the most common cancers worldwide,
accounting for an estimated 226,160 new cases and 160,340
deaths in 2012 in the United States alone [1]. The vast majority of
lung cancers are non-small cell lung cancers (NSCLCs), of which
adenocarcinoma is the most common histology (approximately
50% of all NSCLCs) [2].
The American Joint Committee on Cancer (AJCC) staging
system is currently used to guide treatment decisions and is the
best predictor of prognosis for patients with NSCLC. Although
surgical resection is potentially curative and the most effective
treatment for patients with early-stage NSCLC, 35% to 50% of
patients with AJCC-defined stage I disease will experience
a recurrence within 5 years [3–5]. This indicates that NSCLC is
a very heterogeneous cancer even in the earliest stage, and this
underlying heterogeneity is not well-reflected in the current staging
system. Small fraction of NSCLC patients have an underlying
EGFR mutations or EML4-ALK fusion which are associated with
relatively high response rates to targeted molecular therapies [6–
8]. However, for the majority of adenocarcinoma patients, we do
not yet have any validated biomarkers to predict overall outcome
or to guide treatment selection. Thus, to improve patient care and
management, it is important to further characterize molecular
subgroups significantly associated with this differential response to
standard treatment and to develop models to predict those who
would receive greatest benefit from these treatments.
Recent advances in technology allow unbiased genome-wide
screening of potential markers or gene-expression signatures that
might reflect prognosis. This approach has shown potential success
in identifying prognostic and predictive markers in breast cancer
[9]. Similar approaches have been applied to NSCLC and
prognostic or predictive molecular signatures that may be
clinically useful have been found [10–29]. However, the majority
of these studies are limited by a lack of validation with large and
multiple independent cohorts, or lack of a statistical test for the
robustness of the predictive models and their contribution as new
markers in prediction improvement [30]. In the current study, we
applied a genome-wide survey of gene-expression data to
distinguish subgroups of lung adenocarcinoma with distinct
biological characteristics associated with prognosis and then
identify a gene-expression signature that best reflects the biological
and clinical characteristics of each subgroup. We further tested the
robustness of our new prognostic gene-expression signature using
PLOS ONE | www.plosone.org 1 September 2012 | Volume 7 | Issue 9 | e44225
several statistical approaches and multiple independent cohorts.
Finally, we performed pathway analysis to study the biological
differences that characterize each group.
Methods
Patients and Gene Expression Data
All clinical and gene expression data were collected previously
and are available from public databases. Gene expression and
clinical data from the National Cancer Institute (NCI) Director’s
Challenge Consortium were obtained from the caArray database
at the NCI (https://caarraydb.nci.nih.gov/caarray; experiment
ID, jacob-00182). This data set consisted of 4 different patient
cohorts, including Toronto/Canada (TC, n= 82), Memorial
Sloan-Kettering Cancer Center (MSKCC, n= 104), H. Lee Moffit
Cancer Center (HLM, n=79), and University of Michigan
Cancer Center (UM, n= 177) [18]. For exploration and the
discovery of a potential prognostic gene-expression signature and
validation of the signature, patients were divided into 2 groups.
Patients from the TC and MSKCC cohorts were combined for
discovery of the signature (TM cohort, n = 186). Patients from the
HLM and UM cohorts were used as the first validation set (HM
cohort, n = 256). Gene-expression and clinical data from Massa-
chusetts General Hospital (MGH cohort, n = 125) were obtained
from the public website of the Broad Institute (http://www.
broadinstitute.org/mpr/lung) [11] and used as a second validation
set. The data from the Duke Institute for Genome Sciences and
Policy (Duke cohort, n = 58) were obtained from the public website
of Duke University (http://data.cgt.duke.edu/oncogene.php) [22]
and used as a third validation set. The data from Aichi Cancer
Center (ACC cohort, n = 117) were obtained from the National
Center for Biotechnology Information (NCBI) Gene Expression
Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo,
accession number GSE13213) [21] and used as the fourth
validation set.
Although overall survival (OS) and recurrence free survival
(RFS) were available for the NCI Director’s Challenge cohorts
(TM and HM), only OS data were available for remaining cohorts
(MGH, Duke, and ACC). Adjuvant chemotherapy data were
available only for the TM, HM, and ACC cohorts. Of the 442
patients in TM and HM cohorts, 89 (39 in AJCC stage I, 27 in
stage II, 22 in stage III, and 1 with unknown stages) received
standard adjuvant chemotherapy. The remaining patients did not
receive chemotherapy (n= 233) or treatment data were not
available (n = 120). No patient in the ACC cohort received
adjuvant chemotherapy. RFS was defined in a previous study as
the time from surgery to the first confirmed relapse and was
censored when a patient died or was alive without recurrence at
last contact. Table 1 shows the pathological and clinical
characteristics of the patients in all 5 cohorts. All patients had
undergone surgical resection as their primary treatment.
Statistical Analysis of Microarray Data
Biometric Research Branch (BRB)-ArrayTools were used for
statistical analysis of the gene-expression data [31], and all other
statistical analyses were performed in the R language environment
(http://www.r-project.org). Except for data from the ACC cohort,
all gene-expression data were generated using the Affymetrix
(Santa Clara, CA) platform (U95A for the MGH cohort, U133A
for the TM and HM cohorts, and U133 plus 2.0 for the Duke
cohorts). Raw data from the Affymetrix platform were down-
loaded from public databases and normalized using a robust multi-
array averaging method [32]. Data from the ACC cohort were
generated using the Agilent whole-genome microarray platform,
and pre-normalized data were downloaded and used for analysis.
We identified genes that were differentially expressed between
the 2 classes using a random-variance t-test. Differences in gene
expression between the 2 classes were considered statistically
significant if their p value was less than 0.001. Cluster analysis was
performed with Cluster and Treeview [33]. To predict the class of
the independent patient cohort, we adopted a previously de-
veloped model [34–36]. Briefly, gene-expression data in the
training set (the TM cohort) were combined to form a series of
classifiers according to the compound covariate predictor (CCP)
algorithm as described in previous publications [37] and the
robustness of the classifier was estimated by the misclassification
rate determined during leave-one-out cross-validation (LOOCV)
of the training set. When applied to the independent validation
sets, prognostic significance was estimated by evaluating the
differences between Kaplan-Meier plots and log-rank tests
between the 2 predicted subgroups of patients. After LOOCV,
the sensitivity and specificity of the prediction models were
estimated by the fraction of samples correctly predicted.
Multivariate Cox proportional hazard regression analysis was
used to evaluate independent prognostic factors associated with
survival, and we used gene signature, tumor stage, and pathologic
characteristics as covariates. For each clinical variable, Harrell’s
concordance index (c-index) was calculated as a measure of
predictive accuracy [38]. Interpretation of the c-index is similar to
that of the area under a receiver operating characteristic curve.
The higher the c-index, the more informative the variable is about
a patient’s outcome. The c-index analysis was carried out using the
Harrell Miscellaneous (HMISC) package in the R language
environment. The confidence interval (CI) of the c-index was
estimated using 1000 bootstrap resamplings. A p value of less than
0.05 was considered statistically significant, and all tests were 2-
tailed.
Gene Network Analysis
IngenuityTM Pathways Analysis (IPA, Ingenuity SystemsH) was
used for gene network analysis. Gene network analysis was carried
out by using a global molecular network developed from
information contained in the Ingenuity knowledge Base. Out of
470 gene features, 468 were mapped to the Ingenuity Knowledge
Base. Identified gene networks were ranked according to scores
provided by IPA. The score is the likelihood of a set of genes being
found in the networks due to random chance. For example, a score
of 3 indicates that there is a 1/1000 chance that the focus genes
are in a network due to random chance.
Results
Discovery, Development, and Validation of a Prognostic
Gene Expression Signature
To find potential prognostic subgroups of lung adenocarcinoma
with distinct biological characteristics, we collected gene expres-
sion data from previous studies and divide them into 5
independent cohorts (one exploration cohort and 4 validation
cohorts) (Table 1). Hierarchical clustering analysis of the gene
expression data from the exploration data set (TM cohort, n = 186)
revealed 2 distinct subgroups (clusters) of lung adenocarcinoma
(Fig. 1A). Subsequent analysis of the clinical data showed
a significant difference in clinical outcomes between the 2
subgroups. The OS rates of patients in cluster C1 were
significantly lower than those of patients in cluster C2 (3-year
survival rate: 63.7% [cluster C1] vs 90.1% [cluster C2];
p=1.561025 by x2-test). The hazard ratio (HR) for death of
Prognostic Subtypes of Lung Adenocarcinoma
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cluster C1 was 2.36 (95% CI, 1.35 to 4.13; p=0.002). The
significance trend remained the same for RFS (3-year RFS rate:
48.8% [cluster C1] vs 68.7% [cluster C2]; p=0.009 by x2-test).
The HR for recurrence of cluster C1 was 1.58 (95% CI, 1.01 to
2.46; p=0.04). Continuous survival analysis verified that the
patients in cluster C2 had significantly better OS and RFS than
those in cluster C1 (p=0.001 for OS and p=0.02 for RFS, by log-
rank test; Fig. 1B and 1C).
We next sought to identify a limited number of genes whose
expression was tightly associated with the 2 subgroups. By
applying a stringent threshold cutoff (p,0.001 and at least a 2-
fold difference between subgroups), we identified 193 gene features
differentially expressed between 2 subgroups (Fig. S1 and Table
S1). Of note, the expression of many genes involved in cell
proliferation and cell cycle regulation, such as CCNB1, TOP2A,
AURKA, CDC2, and FOXM1, was significantly higher (p,0.001,
by t-test) in patients in the poor-prognosis subgroup (C1),
indicating that tumors in the C1 subgroup had higher cell
proliferation rates. Thus, we renamed the 2 clusters C1 and C2 as
cluster F (for ‘‘fast-growing tumors’’) and cluster S (for ‘‘slow-
growing tumors’’), respectively.
Independent Validation of the Identified Expression
Signature
With a gene expression signature (193 genes) that accurately
reflected prognosis in TM cohort, we next sought to validate the
association of the gene signature with prognosis in 4 independent
patient cohorts (HM, MGM, Duke, and ACC cohort). For this
validation, previously established data training and prediction
methods [34–36] were applied to gene expression data from the
HM cohort (n = 256; Fig. 2A). When lung adenocarcinoma
patients in the HM cohort were stratified according to the
prognostic gene expression signature, Kaplan-Meier plots showed
significant differences in OS (p=9.461024 by log-rank test)
between the 2 subgroups of patients that were predicted by the
CCP (Fig. 2B). The specificity and sensitivity for correctly
predicting subgroup F during LOOCV were 0.881 and 0.975,
respectively.
To assess the robustness of our gene-expression signature, we
applied our prediction method to 2 additional independent
validation cohorts (MGH cohort, n = 125; Duke cohort, n = 58).
Consistent with the results from the HM cohort, the expression
signature successfully discriminated patients with poor prognosis
(subgroup F) from those with a better prognosis (subgroup S;
Fig. 2C and 2D). In addition, we further tested the robustness of
the signature using another independent cohort with a different
ethnic background, that is, the 117 Japanese patients with lung
adenocarcinoma from the ACC cohort [21]. When patients in the
ACC cohort were stratified according to their gene expression
signatures, Kaplan-Meier plots showed significant differences in
OS (p=8.161024 by log-rank test) between the 2 predicted
subgroups (Fig. 2E). Taken together, these results demonstrated
the robustness of the gene signature for identifying patients at high
risk for disease recurrence and poorer survival.
Significant Association of the Gene Signature with
Clinical Variables
To evaluate the prognostic value of the gene expression
signature in combination with other clinical variables, including
patient age at diagnosis, disease stage by AJCC criteria, smoking
Table 1. Clinical and Pathological Features of Lung Adenocarcinoma Cancer Patients.
Variable
TM
Cohort
HM
Cohort
MGH
Cohort
Duke
Cohort
ACC
Cohort
(Exploration cohort)
(Validation cohort
1)
(Validation
cohort 2)
(Validation cohort
3)
(Validation cohort
4)
Number of patients 186 256 125 58 117
Men 83 (44.6%) 140 (54.7%) 53 (42.4%) 27 (46.6%) 60 (51.3%)
Women 103 (55.4%) 116 (45.3%) 72 (57.6%) 31 (53.4%) 57 (48.7%)
Age (years) Median 64 66 64 67 61
Range 35–82 33–87 33–88 43–83 31–84
Disease stage I 119 (64.0%) 158 (61.7%) 76 (60.8%) 34 (58.6%) 79 (67.5%)
II 46 (24.7%) 49 (19.2%) 24 (19.2%) 7 (12.1%) 13 (11.1%)
III 21 (11.3%) 47 (18.4%) 10 (8.0%) 14 (24.1%) 25 (21.4%)
IV 0 (0%) 0 (0%) 15 (12.0%) 3 (5.2%) 0 (0%)
NA 2 (0.7%)
Adjuvant chemotherapy
Yes 56 (30.1%) 33 (12.9%) 0 0 0
No 96 (51.6%) 137 (53.5%) 0 0 117 (100%)
NA 34 (18.3%) 86 (33.6%) 125 (100%) 58 (100%) 0
Number of deaths 74 162 71 32 49
Abbreviations: TM, Toronto and Memorial Sloan-Kettering Cancer Center; HM, H. Lee Moffit Cancer Center and University of Michigan; MGH, Massachusetts General
Hospital; ACC, Aichi Cancer Center; NA, Not available.
doi:10.1371/journal.pone.0044225.t001
Prognostic Subtypes of Lung Adenocarcinoma
PLOS ONE | www.plosone.org 3 September 2012 | Volume 7 | Issue 9 | e44225
status, sex, and mutation status of certain oncogenes and tumor
suppressor genes (i.e., KRAS, EGFR, and TP53), univariate and
multivariate Cox proportional hazards regression analyses were
performed in the ACC cohort. All patients in this cohort received
uniform treatment (curative resection without adjuvant chemo-
therapy) thus minimizing confounding factors associated with
different treatments. In the univariate analysis, both disease stage
and the gene-expression signature were significantly associated
with OS (p=2.1761024 and p=0.001, respectively). In the
multivariate analysis, disease stage and gene expression signature
maintained their significance (p=0.002 and p=0.01, respectively;
Table 2).
In addition to performing multivariate analysis, we assessed our
new prognostic signature’s potential using the ‘‘drop in concor-
dance index’’ approach [30,39]. Briefly, we generated prediction
models using all clinical variables used in the multivariate analysis.
While the best model was constructed using all of the variables, test
models each lacking 1 variable were generated and compared with
the best model. In each comparison, the predictive value of each
variable was weighted by measuring the decreased value of the c-
index in each test model. Omission of the gene signature in the
prediction model caused the largest decrease in the c-index value
(Table S2), suggesting that the signature not only retains its
Figure 1. Hierarchical clustering analysis of gene expression data from the discovery cohort. (A) Hierarchical clustering of gene-
expression data from 186 patients with lung adenocarcinoma in the discovery (Toronto/Canada and Memorial Sloan-Kettering Cancer Center [TM])
cohort. Genes with an expression level that was at least 2-fold different from the median value across tissues in at least 20 tissues were selected for
hierarchical clustering analysis (3036 gene features). The data are presented in matrix format, where each row represents an individual gene and each
column represents a tissue. Each cell in the matrix represents the expression level of a gene feature in an individual tissue. The red and green color in
the cells reflects the genes’ relatively high and low expression levels, respectively, as indicated in the scale bar (a log2-transformed scale). Kaplan-
Meier plots of the (B) overall survival (OS) and (C) recurrence-free survival (RFS) of patients with lung adenocarcinoma in the TM cohort. Patients were
stratified according to gene-expression patterns (creating two clusters, C1 and C2). RFS data are currently not available from 20 patients.
doi:10.1371/journal.pone.0044225.g001
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prognostic relevance over the classical pathological prognostic
features but also significantly improves the prediction accuracy.
The independence of the new prognostic gene expression
signature over the current staging system was further supported by
analysis of pooled data from all 4 validation cohorts (n = 556). As
expected, the OS of subgroup F was significantly worse than that
of subgroup S (p=3.061028 by log-rank test) when all patients
were included in the analysis (Fig. S2B). In subset analysis, the
gene-expression signature successfully identified poorer survival for
both stage I (p=0.006 by log-rank test) and stage II patients
(p=0.03 by log-rank test; Fig. S2C and S2D). Taken together,
these findings strongly demonstrate that our new prognostic gene-
expression signature is independent from the current staging
system.
Association of the Gene Signature with Potential Benefit
from Adjuvant Chemotherapy
Of the 442 patients from TM and HM cohorts, adjuvant
chemotherapy data were available for 322 patients. Thus, we next
sought to determine whether the new gene expression signature
could predict a potential benefit from adjuvant chemotherapy. To
examine the association of the gene signature with response to
adjuvant chemotherapy, we performed subset analysis with
patients in AJCC stage III, a stage for which the benefit of
adjuvant chemotherapy has been previously demonstrated [40–
42]. Patients with stage III disease (n = 49) were subdivided into 2
subgroups (F or S), and the difference in OS was independently
assessed. Adjuvant chemotherapy significantly affected OS in
patients in subgroup F (3-year OS rate, 29.4% [adjuvant
chemotherapy] vs 16.7% [no adjuvant chemotherapy]; p=0.009
by log-rank test; Fig. 3B). However, there was not a significant
benefit from adjuvant chemotherapy for patients in subgroup S (3-
year OS rate, 50% [adjuvant chemotherapy] vs 60% [no adjuvant
chemotherapy]; p=0.58 by log-rank test; Fig. 3C). When a Cox
regression model was applied, the interaction of subgroups with
adjuvant chemotherapy reached a significance level of 0.03.
Consistent with the Kaplan-Meier plot and log-rank test, the
estimated HR for death for adjuvant chemotherapy in subgroup F
was 0.44 (95% CI, 0.2 to 0.95; p=0.036), while the HR for death
for adjuvant chemotherapy in subgroup S was 1.96 (95% CI, 0.56
to 6.88; p=0.29). This suggests a benefit of adjuvant therapy only
in the F subgroup and potential harm associated with adjuvant
treatment in the S subgroup. A similar trend was observed in the
Stage II patients, although it did not reach statistical significance
(p=0.22) (Fig. S3). In the Stage I patients, there was an overall
trend towards worse outcome with adjuvant chemotherapy (Fig.
S3).
Biological Insights from the Conserved Prognostic Gene-
Expression Signature
To elucidate the biological characteristics of the subgroup with
poor prognosis (subgroup F), we attempted to identify genes whose
expression differed between the ‘‘F’’ and ‘‘S’’ subgroups across all
data sets. We excluded gene-expression data from the MGH
cohort in this analysis to maximize the compatibility of the data
sets, since the MGH data were generated using an old microarray
platform (U95A) with a limited number of gene probes. We
applied a stringent cut-off (p,0.001) to avoid inclusion of potential
false-positive genes. When they were all compared together, 470
genes were shared by all 4 cohorts (Fig. 4A).
We next performed pathway analysis on the 470 genes using the
Ingenuity Pathway Analysis tool that is a controlled vocabulary-
based pathway tool. This analysis revealed a series of putative
networks. Functional connectivity of the top network revealed
a strong over-representation of the E2F1 pathway in patients in
the F subgroup (Fig. S4), suggesting that its activation may be
Figure 2. Construction of the prediction model and evaluation of predicted outcome. (A) Schematic overview of the strategy used for
constructing prediction models and evaluating the predicted outcomes based on gene expression signatures. Kaplan-Meier plots of the overall
survival (OS) of the 2predicted groups of lung adenocarcinoma patients in the (B) HM, (C) MGH, (D) Duke, (E) and ACC cohorts. The differences
between groups were significant, as indicated by the log-rank test. The + symbols in panels B–E indicate censored data.
doi:10.1371/journal.pone.0044225.g002
Table 2. Univariate and Multivariate Cox Proportional Hazard Regression Analyses of Overall Survival in the ACC Cohort (n = 117).
Univariate Multivariate
Variable Hazard Ratio (95% CI) p Hazard Ratio (95% CI) P
Sex
(M vs F)
1.36 (0.77–2.38) 0.28 1.52 (0.66–3.4) 0.31
Age 1.0 (0.97–1.03) 0.67 1.0 (0.97–1.03) 0.68
EGFR
(mutant vs WT)
1.0 (0.57–1.8) 0.95 1.5 (0.77–2.8) 0.23
KRAS
(mutant vs WT)
1.5 (0.7–3.2) 0.27 1.3 (0.57–3.3) 0.5
TP53
(mutant vs WT)
1.35 (0.76–2.4) 0.29 1.1(0.6–2.0) 0.72
Smoking
(yes vs no)
1.36 (0.77–2.4) 0.28 0.76 (0.33–1.7) 0.53
Disease stage
(I, II, III)
1.78 (1.3–2.4) 2.1761024 1.65 (1.2–2.2) 0.002
Gene signature
(F vs S)
2.76 (1.4–5.1) 0.001 2.4 (1.2–4.8) 0.01
Abbreviations: CI, confidence interval; M, male; F (sex), female; WT, wild-type; F (gene signature), fast-growing; S, slow-growing.
doi:10.1371/journal.pone.0044225.t002
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a key genetic determinant associated with the poorer survival of
lung adenocarcinoma patients in this subgroup. Expression of
EZH2, which is frequently overexpressed in many cancers [43],
was also significantly higher in subgroup F, indicating the
importance of the E2F1-EZH2 network in the progression of lung
adenocarcinoma. TP53 was overrepresented in another network
(Fig. S5). Interestingly, many genes negatively regulated by TP53
were overexpressed in the TP53 networks. For example, previous
studies have demonstrated that expression of PRC1 and BUB1 are
directly suppressed by TP53 [44,45], but their expression is
significantly upregulated in subgroup F, suggesting that the
biological activity of TP53 may be substantially lost in this
subgroup.
Discussion
By analyzing gene-expression data from lung adenocarcinoma
tissues, we identified a limited number of genes (193 genes) whose
expression is significantly associated with prognosis. The robust-
ness of this gene-expression signature was validated in 4
independent cohorts with a total of 556 patients. Since current
staging systems and biomarkers are limited in their ability to assess
risk of recurrence and benefit from adjuvant chemotherapy in lung
adenocarcinoma, our new gene-expression signature may repre-
sent a tool that could help further refine treatment decisions based
on the tumors’ molecular profiles.
For development and validation of a robust, prognostic gene
expression signature, we applied 2 independent but complemen-
tary methods. Unsupervised hierarchical clustering was first
applied to identify subgroups with significant differences in
biological characteristics as well as prognosis. In the second
approach, supervised prediction models were applied to validate
the association of the signature with clinical outcomes in 4
independent patient cohorts. The robustness of the 193-gene
signature was supported by the high sensitivity (.0.9) and
specificity (.0.8) values seen during training of the prediction
models within the discovery cohort and a significant association
between the predicted outcome and patient prognosis in 4 test
cohorts. In addition to its robustness, the prognostic gene
signature’s independence as a prognostic marker was supported
by the results of vigorous tests using various approaches. First, the
signature could identify high-risk patients among those with early
stage adenocarcinoma (stage I and II). Second, in multivariate
analysis, the signature was one of the most significant predictive
factors for OS. Third, the signature was the most significant
contributor to the predicted OS in models using the drop-in c-
index approach. Taken together, these results strongly support
that the 2 subgroups of lung adenocarcinoma predicted here are
novel prognostic clinical subgroups that are not recognized by the
current staging system.
Subset analysis of patients with available chemotherapy data
strongly suggested that the 193-gene signature can predict which
patients will benefit from adjuvant chemotherapy. In patients with
stage III disease, adjuvant chemotherapy was significantly
associated with improved outcome for patients in subgroup F
(HR, 0.44; 95% CI, 0.2 to 0.95; p=0.036), whereas its benefit was
not statistically significant for patients in subgroup S (HR, 1.96;
95% CI, 0.56 to 6.88; p=0.29). Thus, our newly identified gene
signature showed both a prognostic and predictive association.
Interestingly, our prognostic gene expression signature lacks
overlapped genes with previously identified prognostic gene
expression signatures. For example, of 193 genes, only one gene
is common with the prognostic signature discovered in Japanese
patients [21]. Likewise, no or only few genes were shared with
other signatures such as EGFR-mutation signature [29], stage I
specific prognostic signature [27], and ALK-associated gene
expression signature [28]. Moreover, when different signatures
were compared all together in multiple-comparison manner, only
few genes were shared among the signatures. Our finding is
consistent with previous study in breast cancer showing absence of
gene overlap although concordance of predicted outcome is very
high [46].
Figure 3. Significant association of the 2 gene-expression signature subtypes with adjuvant chemotherapy. (A) Kaplan-Meier plots of
the overall survival (OS) of adenocarcinoma patients in the TM and HM cohorts. The data were plotted according to the prognostic gene-expression
signature (subgroups F and S). Kaplan-Meier plots of patients in (B) subgroup F or (C) subgroup S with stage III disease. Data were plotted according
to whether patients were treated with or without adjuvant chemotherapy (CTX).
doi:10.1371/journal.pone.0044225.g003
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Overexpression of EZH2, a methyltransferase that catalyzes H3
trimethylation on lysine 27 and is essential for stem cell self-
renewal [47], in subgroup F is in good agreement with previous
studies. Its altered expression has been linked to the aggressive
progression of many cancers through its activation of angiogenesis
and maintenance of the tumor-initiating cell (or cancer stem cell)
population [48]. EZH2 is a newly identified downstream target of
E2F1 [49], which is a major downstream effector of the RB tumor
suppressor and has a pivotal role in controlling cell cycle
progression [50]. Expression of E2F1’s well-known downstream
Figure 4. Cross comparison of gene lists from 4 independent cohorts of lung adenocarcinoma patients. (A) Venn diagram of genes
whose expression is significantly different between subgroups F and S. a univariate test (2-sample t-test) with multivariate permutation test (10,000
random permutations) was applied. In each comparison, we applied a cut-off P-value of less than 0.001 to retain genes whose expression was
significantly different between the 2 groups of tissues examined. (B) Expression patterns of selected genes shared in 4 lung adenocarcinoma cohorts.
The expression of 470 genes is commonly up- or down-regulated in all 4 cohorts. Colored bars at the top of the heat map represent samples as
indicated.
doi:10.1371/journal.pone.0044225.g004
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target genes was significantly upregulated in subgroup F (Fig. S4),
indicating that E2F1 was highly activated in subgroup F and that
E2F1-mediated regulation of EZH2 may be a key genetic event
associated with poor prognosis in lung adenocarcinoma.
Expression of TYMS (thymidylate synthase) was also higher in
subgroup F, which is in good agreement with previous studies
showing that higher expression of TYMS is significantly associated
with poorer prognosis in lung adenocarcinoma [51,52]. Peme-
trexed, a potent inhibitor of TYMS [53], has emerged as one of
the most active agents for the treatment of patients with advanced
NSCLC. Previous studies have demonstrated that higher TYMS
expression is associated with a lower chemotherapeutic effect of
pemetrexed in patients with a variety of solid tumors [54–56] and
forced overexpression of TYMS in NSCLC cells reduced sensitivity
to pemetrexed [57]. Since expression of TYMS is significantly
higher in subgroup F, our data suggest that pemetrexed may show
limited antitumor activity for patients in this subgroup. By
contrast, patients in subgroup S may benefit from pemetrexed
because they have lower expression of TYMS. Thus, the 2 newly
identified subgroups of lung adenocarcinoma not only well reflect
previously recognized clinical characteristics of lung adenocarci-
noma but may also provide guidance for treatment regimens.
In a recent evaluation of all prognostic gene expression
signatures for lung cancer [39,58], 2 important criteria were
suggested for a new prognostic signature to be accepted by the
medical community. First, the new signature should be rigorously
tested for statistical validation and reproducibility in large
multiple-patient cohorts. Second, the new signature should show
good predictive power over and above current risk factors. Our
prognostic signature fulfills these 2 suggested criteria, as evidenced
by validation of the signature in 4 independent cohorts (a total of
556 patients), independence from the current staging system,
improvement of predictive power when included in the prediction
model, and identification of high risk-patients with very early-stage
disease. Although interesting, our analysis has some limitations
because we only used mRNA expression level of genes that is not
always correlated with their biological activity. Thus, other
approaches better reflecting biological activity like proteomics
should be used for finding better functional markers in future
study.
In conclusion, using gene-expression data from multiple
cohorts, we identified 2 new prognostic subgroups of lung
adenocarcinoma that show significant differences in patient
survival. The 193-gene signature can identify patients with a high
risk of recurrence, as well as patients who would have benefited
from adjuvant chemotherapy. This study clearly demonstrated
that our gene-expression signature reflects the molecular char-
acteristics of different subgroups of lung adenocarcinoma and
provides an opportunity to rationally design future clinical trials so
that patients who might benefit from adjuvant chemotherapy can
be identified. Our results, if confirmed in prospective studies, may
improve patient care by providing more practical guidance for
treatment.
Supporting Information
Figure S1 Genes differentially expressed between clus-
ter C1 (F) and cluster C2 (S) in TM cohort (n= 186). Genes
were selected by univariate test (2-sample t-test) with multivariate
permutation test and stringent cut-off (P,0.001 and .2-fold
difference) was applied to retain genes whose expression is
significantly different between the 2 groups of tissues examined
(193 genes). The data are presented in matrix format, where rows
represent individual gene and columns represent each tissue. Each
cell in the matrix represents the expression level of a gene feature
in an individual tissue. The red and green color in cells reflect
relative high and low expression levels respectively as indicated in
the scale bar (log2 transformed scale).
(EPS)
Figure S2 Kaplan-Meier plots of the overall survival
(OS) in patients in all validation cohorts. Patients were
stratified by (A) disease stage or (B) gene expression signature.
Subset analysis showed that the gene expression signature was
predictive in patients with (C) stage I or (D) stage II disease. Of 556
patients, stage data are not available from 2 patients.
(EPS)
Figure S3 Kaplan-Meier plots of the overall survival
(OS) in patients with Stage I and Stage II disease in TM
and HM cohorts. The data were plotted according to whether
patients were treated with or without adjuvant chemotherapy
(CTX). (A) Subtype F in stage I. (B) Subtype S in stage I. (C)
Subtype F in stage II. (D) Subtype S in stage II.
(EPS)
Figure S4 E2F1 networks in F subgroup of lung
adenocarcinoma. IngenuityH pathway analysis revealed that
networks of genes considerably associated with the E2F1in
conserved gene expression data from the 4 cohorts. Upregulated
and downregulated genes in the F subgroup are indicated by red
and green, respectively. The lines and arrows represent functional
and physical interactions and the directions of regulation from the
literature.
(EPS)
Figure S5 TP53 networks the in F subgroup of lung
adenocarcinoma. IngenuityH pathway analysis revealed that
networks of genes considerably associated with the TP53 in
conserved gene expression data from the 4 cohorts. Upregulated
and downregulated genes in the F subgroup are indicated by red
and green, respectively. The lines and arrows represent functional
and physical interactions and the directions of regulation from the
literature.
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Table S1 Summary of 193 gene features in prognostic
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Variables in ACC Cohort.
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